{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T20:53:41Z","timestamp":1775249621161,"version":"3.50.1"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T00:00:00Z","timestamp":1539734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["12 RO1HL128714"],"award-info":[{"award-number":["12 RO1HL128714"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Ciencia y Tecnologia","doi-asserted-by":"publisher","award":["13 2005000283"],"award-info":[{"award-number":["13 2005000283"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>In uremic animals, vitamin D receptor (VDR) agonists like paricalcitol (Pc) attenuate cardiac hypertrophy, but this effect has not been replicated consistently in humans with chronic kidney disease. Elevated fibroblast growth factor 23 (FGF23) levels cause cardiac hypertrophy with activation of the myocardial calcineurin\/nuclear factor of activated T cell (NFAT) axis and may antagonize the cardioprotective effects of VDR agonist therapy. We hypothesized that the effectiveness of Pc may depend on the prevailing circulating levels of FGF23 and could be potentiated by the combined administration of a pan-FGF23 receptor (FGFR) blocker agent (PD173074).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>In rats with 5\/6 nephrectomy treated with Pc or PD173074 or both agents concurrently, myocardial mRNA expression of renin\u2013angiotensin system, VDR, FGFR4, and calcineurin\/NFAT target genes was determined. In adolescents on hemodialysis, we analyzed sequential echocardiograms, blood pressures and serial FGF23 measurements, and their relations to the cumulative administered dose of parenteral Pc.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The ratio of Pc dose\/plasma levels of FGF23 correlated inversely (P &amp;lt; 0.005) with the cardiac mass in uremic rats and in hemodialysis patients, independently of hypertension. Despite persistently elevated FGF23 levels and myocardial FGFR4 activation, Pc suppressed upregulated myocardial calcineurin\/NFAT target genes, and the effects were amplified by coadministration of PD173074.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>The beneficial effects of Pc on uremic cardiac hypertrophy are counterbalanced by the increased FGF23 levels. Blockade of FGF23-mediated signaling increased the Pc-induced suppression of the myocardial calcineurin\/NFAT system. Higher doses of Pc should be considered in the treatment of patients with uremic cardiomyopathy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajh\/hpy154","type":"journal-article","created":{"date-parts":[[2018,10,13]],"date-time":"2018-10-13T15:08:46Z","timestamp":1539443326000},"page":"34-44","source":"Crossref","is-referenced-by-count":27,"title":["Cardioprotective Effects of Paricalcitol Alone and in Combination With FGF23 Receptor Inhibition in Chronic Renal Failure: Experimental and Clinical Studies"],"prefix":"10.1093","volume":"32","author":[{"given":"Brian","family":"Czaya","sequence":"first","affiliation":[{"name":"Katz Family Drug Discovery Center and Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA"},{"name":"Division of Nephrology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wacharee","family":"Seeherunvong","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurav","family":"Singh","sequence":"additional","affiliation":[{"name":"Katz Family Drug Discovery Center and Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Yanucil","sequence":"additional","affiliation":[{"name":"Katz Family Drug Discovery Center and Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA"},{"name":"Division of Nephrology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Department of Surgery and Immunopathology, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmir","family":"Quiroz","sequence":"additional","affiliation":[{"name":"Hospital Universitario, Servicio de Nefrologia y Laboratorio de Inmunobiologia, Instituto Venezolano de Investigaciones Cient\u00edficas (IVIC)-Zulia, Maracaibo, Venezuela"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Grabner","sequence":"additional","affiliation":[{"name":"Katz Family Drug Discovery Center and Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA"},{"name":"Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chryso","family":"Katsoufis","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sethuraman","family":"Swaminathan","sequence":"additional","affiliation":[{"name":"Division of Pediatric Cardiology, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Abitbol","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Rodriguez-Iturbe","sequence":"additional","affiliation":[{"name":"Hospital Universitario, Servicio de Nefrologia y Laboratorio de Inmunobiologia, Instituto Venezolano de Investigaciones Cient\u00edficas (IVIC)-Zulia, Maracaibo, Venezuela"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Faul","sequence":"additional","affiliation":[{"name":"Katz Family Drug Discovery Center and Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA"},{"name":"Division of Nephrology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6629-3158","authenticated-orcid":false,"given":"Michael","family":"Freundlich","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,10,17]]},"reference":[{"key":"2022101313570101900_CIT0001","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/ki.1995.22","article-title":"Clinical and echocardiographic disease in patients starting end-stage renal disease therapy","volume":"47","author":"Foley","year":"1995","journal-title":"Kidney Int"},{"key":"2022101313570101900_CIT0002","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1681\/ASN.2011111115","article-title":"Cardiovascular disease in children with chronic kidney disease","volume":"23","author":"Mitsnefes","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2022101313570101900_CIT0003","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1681\/ASN.2012121197","article-title":"BP control and left ventricular hypertrophy regression in children with CKD","volume":"25","author":"Kupferman","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2022101313570101900_CIT0004","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/ki.2008.690","article-title":"Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure","volume":"75","author":"Siedlecki","year":"2009","journal-title":"Kidney Int"},{"key":"2022101313570101900_CIT0005","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ppedcard.2015.11.001","article-title":"Chronic kidney disease and cardiac morbidity-what are the possible links","volume":"41","author":"Freundlich","year":"2016","journal-title":"Prog Ped Cardiol"},{"key":"2022101313570101900_CIT0006","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jsbmb.2010.03.026","article-title":"Myocardial effects of VDR activators in renal failure","volume":"121","author":"Mizobuchi","year":"2010","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2022101313570101900_CIT0007","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1038\/kisup.2011.26","article-title":"Vitamin D and heart disease","volume":"1","author":"Pilz","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"2022101313570101900_CIT0008","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"2022101313570101900_CIT0009","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Guti\u00e9rrez","year":"2009","journal-title":"Circulation"},{"key":"2022101313570101900_CIT0010","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00467-012-2224-7","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis","volume":"27","author":"Seeherunvong","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"2022101313570101900_CIT0011","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2215\/CJN.02110217","article-title":"FGF23 and left ventricular hypertrophy in children with CKD","volume":"13","author":"Mitsnefes","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022101313570101900_CIT0012","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1172\/JCI0215219","article-title":"1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system","volume":"110","author":"Li","year":"2002","journal-title":"J Clin Invest"},{"key":"2022101313570101900_CIT0013","doi-asserted-by":"crossref","first-page":"16810","DOI":"10.1073\/pnas.0611202104","article-title":"Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals","volume":"104","author":"Bodyak","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022101313570101900_CIT0014","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/ajh\/hpt177","article-title":"Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats","volume":"27","author":"Freundlich","year":"2014","journal-title":"Am J Hypertens"},{"key":"2022101313570101900_CIT0015","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/ki.2008.408","article-title":"Suppression of renin-angiotensin gene expression in the kidney by paricalcitol","volume":"74","author":"Freundlich","year":"2008","journal-title":"Kidney Int"},{"key":"2022101313570101900_CIT0016","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1159\/000178251","article-title":"Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats","volume":"29","author":"Husain","year":"2009","journal-title":"Am J Nephrol"},{"key":"2022101313570101900_CIT0017","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","article-title":"Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy","volume":"22","author":"Grabner","year":"2015","journal-title":"Cell Metab"},{"key":"2022101313570101900_CIT0018","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.2005111185","article-title":"Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D","volume":"17","author":"Liu","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2022101313570101900_CIT0019","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2010.352","article-title":"Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism","volume":"79","author":"Wesseling-Perry","year":"2011","journal-title":"Kidney Int"},{"key":"2022101313570101900_CIT0020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4049\/jimmunol.160.1.209","article-title":"Nuclear factor of activated T cells (NFAT) as a molecular target for 1alpha,25-dihydroxyvitamin D3-mediated effects","volume":"160","author":"Takeuchi","year":"1998","journal-title":"J Immunol"},{"key":"2022101313570101900_CIT0021","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/CIRCULATIONAHA.111.032680","article-title":"Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy","volume":"124","author":"Chen","year":"2011","journal-title":"Circulation"},{"key":"2022101313570101900_CIT0022","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.ajpath.2012.12.011","article-title":"Vitamin D down-regulates TRPC6 expression in podocyte injury and proteinuric glomerular disease","volume":"182","author":"Sonneveld","year":"2013","journal-title":"Am J Pathol"},{"key":"2022101313570101900_CIT0023","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/ndt\/gfw454","article-title":"Vitamin D treatment attenuates cardiac FGF23\/FGFR4 signaling and hypertrophy in uremic rats","volume":"32","author":"Leifheit-Nestler","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2022101313570101900_CIT0024","doi-asserted-by":"crossref","first-page":"F217","DOI":"10.1152\/ajprenal.00332.2015","article-title":"The fibroblast growth factor receptor mediates the increased FGF23 expression in acute and chronic uremia","volume":"310","author":"Hassan","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022101313570101900_CIT0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0272-6386(99)70260-X","article-title":"Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism","volume":"33","author":"Park","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"2022101313570101900_CIT0026","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1681\/ASN.2013010103","article-title":"Effect of paricalcitol on left ventricular mass and function in CKD\u2013the OPERA trial","volume":"25","author":"Wang","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2022101313570101900_CIT0027","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1007\/s00467-006-0204-5","article-title":"Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients","volume":"21","author":"Seeherunvong","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"2022101313570101900_CIT0028","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00467-017-3675-7","article-title":"Oral paricalcitol: expanding therapeutic options for pediatric chronic kidney disease patients","volume":"32","author":"Freundlich","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"2022101313570101900_CIT0029","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.kint.2016.05.019","article-title":"Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease","volume":"90","author":"Singh","year":"2016","journal-title":"Kidney Int"},{"key":"2022101313570101900_CIT0030","author":"Center of Disease Control and Prevention","year":"2011"},{"key":"2022101313570101900_CIT0031","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1542\/peds.114.S2.555","article-title":"The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents","volume":"114","author":"National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents","year":"2004","journal-title":"Pediatrics"},{"key":"2022101313570101900_CIT0032","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00467-016-3356-y","article-title":"Fibroblast growth factor-23 and renin-angiotensin system levels in vitamin-D-dependent rickets type I","volume":"31","author":"Cuervo","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"2022101313570101900_CIT0033","doi-asserted-by":"crossref","first-page":"E1951","DOI":"10.1210\/jc.2014-2125","article-title":"Lack of FGF23 response to acute changes in serum calcium and PTH in humans","volume":"99","author":"Wesseling-Perry","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2022101313570101900_CIT0034","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1159\/000362251","article-title":"Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease","volume":"39","author":"Seifert","year":"2014","journal-title":"Am J Nephrol"},{"key":"2022101313570101900_CIT0035","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1681\/ASN.2006091028","article-title":"Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats","volume":"18","author":"Mizobuchi","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2022101313570101900_CIT0036","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1093\/ndt\/gft268","article-title":"Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis","volume":"28","author":"Panizo","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2022101313570101900_CIT0037","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/emmm.201303716","article-title":"FGF23 regulates renal sodium handling and blood pressure","volume":"6","author":"Andrukhova","year":"2014","journal-title":"EMBO Mol Med"},{"key":"2022101313570101900_CIT0038","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0008-6363(99)00145-5","article-title":"The renin-angiotensin system and experimental heart failure","volume":"43","author":"Wollert","year":"1999","journal-title":"Cardiovasc Res"},{"key":"2022101313570101900_CIT0039","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1093\/ndt\/gfy006","article-title":"Fibroblast growth factor 23 is induced by an activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts","volume":"33","author":"Leifheit-Nestler","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2022101313570101900_CIT0040","doi-asserted-by":"crossref","first-page":"F1168","DOI":"10.1152\/ajprenal.00606.2015","article-title":"FGF23 from bench to bedside","volume":"310","author":"Kovesdy","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022101313570101900_CIT0041","doi-asserted-by":"crossref","first-page":"e44161","DOI":"10.1371\/journal.pone.0044161","article-title":"A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model","volume":"7","author":"Dai","year":"2012","journal-title":"PLoS One"},{"key":"2022101313570101900_CIT0042","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/ndt\/gfw105","article-title":"Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis","volume":"32","author":"de Jong","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2022101313570101900_CIT0043","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1681\/ASN.2017040412","article-title":"Cardiovascular effects of renal distal tubule deletion of the FGF receptor 1 gene","volume":"29","author":"Han","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2022101313570101900_CIT0044","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1681\/ASN.2010121251","article-title":"Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease","volume":"22","author":"de Borst","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2022101313570101900_CIT0045","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jsbmb.2012.09.007","article-title":"Liganded vitamin D receptor displays anti-hypertrophic activity in the murine heart","volume":"136","author":"Chen","year":"2013","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2022101313570101900_CIT0046","doi-asserted-by":"crossref","first-page":"e0128655","DOI":"10.1371\/journal.pone.0128655","article-title":"1,25 Dihydroxyvitamin D3 inhibits TGF\u03b21-mediated primary human cardiac myofibroblast activation","volume":"10","author":"Meredith","year":"2015","journal-title":"PLoS One"},{"key":"2022101313570101900_CIT0047","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/ndt\/gfv421","article-title":"Induction of cardiac FGF23\/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease","volume":"31","author":"Leifheit-Nestler","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2022101313570101900_CIT0048","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1128\/MCB.19.6.4191","article-title":"A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene: vitamin D receptor competes for DNA binding with NFAT1 and stabilizes c-Jun","volume":"19","author":"Towers","year":"1999","journal-title":"Mol Cell Biol"},{"key":"2022101313570101900_CIT0049","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1681\/ASN.2017070772","article-title":"Longitudinal FGF23 trajectories and mortality in patients with CKD","volume":"29","author":"Isakova","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2022101313570101900_CIT0050","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial","volume":"307","author":"Thadhani","year":"2012","journal-title":"JAMA"},{"key":"2022101313570101900_CIT0051","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/CIRCHEARTFAILURE.112.000105","article-title":"FGF23 modifies the relationship between vitamin D and cardiac remodeling","volume":"6","author":"Ky","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2022101313570101900_CIT0052","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5301\/ijao.5000289","article-title":"Differential influence of vitamin D analogs on left ventricular mass index in maintenance hemodialysis patients","volume":"37","author":"Sezer","year":"2014","journal-title":"Int J Artif Organs"},{"key":"2022101313570101900_CIT0053","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/ckj\/sfu074","article-title":"Longitudinal FGF23 and Klotho axis characterization in children treated with chronic peritoneal dialysis","volume":"7","author":"Cano","year":"2014","journal-title":"Clin Kidney J"},{"key":"2022101313570101900_CIT0054","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ahj.2012.09.018","article-title":"Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease","volume":"164","author":"Tamez","year":"2012","journal-title":"Am Heart J"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/32\/1\/34\/46497934\/ajh_32_1_34.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/32\/1\/34\/46497934\/ajh_32_1_34.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:52:02Z","timestamp":1775245922000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/32\/1\/34\/5134078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,17]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,10,17]]},"published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpy154","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1]]},"published":{"date-parts":[[2018,10,17]]}}}